164 related articles for article (PubMed ID: 20017657)
1. Pharmaceutical technology management--profitable business avenue.
Puthli SP
Expert Opin Drug Deliv; 2010 Jan; 7(1):1-5. PubMed ID: 20017657
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical new product development: the increasing role of in-licensing.
Edwards NV
Anesthesiol Clin; 2008 Dec; 26(4):627-36, v. PubMed ID: 19041620
[TBL] [Abstract][Full Text] [Related]
3. Effective executive management in the pharmaceutical industry.
Tran H; Kleiner BH
J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973
[TBL] [Abstract][Full Text] [Related]
4. The changing environment for technological innovation in health care.
Goodman CS; Gelijns AC
Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
[TBL] [Abstract][Full Text] [Related]
5. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. The epiphany of data warehousing technologies in the pharmaceutical industry.
Barrett JS; Koprowski SP
Int J Clin Pharmacol Ther; 2002 Mar; 40(3):S3-13. PubMed ID: 11911607
[TBL] [Abstract][Full Text] [Related]
8. The interaction between intellectual property and drug regulatory systems: global perspectives.
Madden EA
IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
[TBL] [Abstract][Full Text] [Related]
9. Mastering the value chain. An interview with Mark Levin of Millennium Pharmaceuticals. Interview by David Champion.
Levin M
Harv Bus Rev; 2001 Jun; 79(6):108-15, 148. PubMed ID: 11408971
[TBL] [Abstract][Full Text] [Related]
10. New Zealand's drug development industry--strengths and opportunities.
Lockhart MM; Babar ZU; Garg S
N Z Med J; 2010 Jun; 123(1317):52-8. PubMed ID: 20657631
[TBL] [Abstract][Full Text] [Related]
11. Improving the drug selection and development process for combination devices.
Hupcey MA; Ekins S
Drug Discov Today; 2007 Oct; 12(19-20):844-52. PubMed ID: 17933686
[TBL] [Abstract][Full Text] [Related]
12. Advances in knowledge management for pharmaceutical research and development.
Torr-Brown S
Curr Opin Drug Discov Devel; 2005 May; 8(3):316-22. PubMed ID: 15892246
[TBL] [Abstract][Full Text] [Related]
13. R&D technology investments: misguided and expensive or a better way to discover medicines?
Schmid EF; Smith DA
Drug Discov Today; 2006 Sep; 11(17-18):775-84. PubMed ID: 16935744
[TBL] [Abstract][Full Text] [Related]
14. [Medical research and the pharmaceutical industry. Uneasy bedfellows or a prenuptial agreement?].
Cohen AF
Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1438-42. PubMed ID: 11503309
[TBL] [Abstract][Full Text] [Related]
15. Brazil: An emerging partner in drug R&D.
Rodrigues DG
IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical company influences on medication prescribing and their potential impact on quality use of medicines.
Kyle GJ; Nissen LM; Tett SE
J Clin Pharm Ther; 2008 Oct; 33(5):553-9. PubMed ID: 18834371
[TBL] [Abstract][Full Text] [Related]
17. A decade of fragment-based drug design: strategic advances and lessons learned.
Hajduk PJ; Greer J
Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
[TBL] [Abstract][Full Text] [Related]
18. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice.
Charlton BG
Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461
[TBL] [Abstract][Full Text] [Related]
19. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
Bjerrum OJ
Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
[TBL] [Abstract][Full Text] [Related]
20. Redesigner drugs.
Dove A
Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
